PriceTargets.com logo

Hims & Hers Health - HIMS Stock Price Target and Predictions

  • Consensus Rating: Hold
  • Consensus Price Target: $20.71
  • Forecasted Upside: -4.98%
  • Number of Analysts: 16
  • Breakdown:
  • 1 Sell Ratings
  • 8 Hold Ratings
  • 7 Buy Ratings
  • 0 Strong Buy Ratings
$21.80 As of 11/20/2024 01:00 AM ET
▼ -1.73 (-7.35%)

This chart shows the closing price for HIMS by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Hims & Hers Health Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for HIMS and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for HIMS

Analyst Price Target is $20.71
▼ -4.98% Downside Potential
This price target is based on 16 analysts offering 12 month price targets for Hims & Hers Health in the last 3 months. The average price target is $20.71, with a high forecast of $28.00 and a low forecast of $10.00. The average price target represents a -4.98% upside from the last price of $21.80.

This chart shows the closing price for HIMS for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Hold

The current consensus among 16 investment analysts is to hold stock in Hims & Hers Health. This rating changed within the last month from a Moderate Buy consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 6 buy ratings
  • 3 hold ratings
  • 0 sell ratings
Ratings as of
5/30/2023
  • 0 strong buy ratings
  • 7 buy ratings
  • 3 hold ratings
  • 0 sell ratings
Ratings as of
8/28/2023
  • 0 strong buy ratings
  • 6 buy ratings
  • 3 hold ratings
  • 0 sell ratings
Ratings as of
11/26/2023
  • 0 strong buy ratings
  • 6 buy ratings
  • 3 hold ratings
  • 0 sell ratings
Ratings as of
2/24/2024
  • 0 strong buy ratings
  • 8 buy ratings
  • 7 hold ratings
  • 0 sell ratings
Ratings as of
5/24/2024
  • 0 strong buy ratings
  • 8 buy ratings
  • 8 hold ratings
  • 0 sell ratings
Ratings as of
8/22/2024
  • 0 strong buy ratings
  • 8 buy ratings
  • 8 hold ratings
  • 0 sell ratings
Ratings as of
10/21/2024
  • 0 strong buy ratings
  • 7 buy ratings
  • 8 hold ratings
  • 1 sell ratings
Ratings as of
11/20/2024

Latest Recommendations

  • 0 strong buy ratings
  • 7 buy ratings
  • 8 hold ratings
  • 1 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
11/20/2024TD CowenReiterated RatingBuy ➝ Buy$28.00 ➝ $28.00
11/14/2024Bank of AmericaDowngradeBuy ➝ Underperform$32.00 ➝ $18.00
11/8/2024TD CowenBoost TargetBuy ➝ Buy$25.00 ➝ $28.00
11/6/2024Deutsche Bank AktiengesellschaftBoost TargetHold ➝ Hold$23.00 ➝ $27.00
11/5/2024Piper SandlerReiterated RatingNeutral ➝ Neutral$18.00 ➝ $21.00
11/5/2024Canaccord Genuity GroupBoost TargetBuy ➝ Buy$24.00 ➝ $28.00
10/21/2024Bank of AmericaBoost TargetBuy ➝ Buy$23.00 ➝ $25.00
10/14/2024Bank of AmericaBoost TargetBuy ➝ Buy$20.00 ➝ $23.00
9/13/2024Bank of AmericaLower TargetBuy ➝ Buy$24.00 ➝ $20.00
8/22/2024Needham & Company LLCInitiated CoverageBuy$24.00
8/9/2024Imperial CapitalDowngradeOutperform ➝ In-Line
8/7/2024Deutsche Bank AktiengesellschaftBoost TargetHold ➝ Hold$16.00 ➝ $23.00
8/6/2024Piper SandlerReiterated RatingNeutral ➝ Neutral$18.00 ➝ $18.00
7/18/2024Truist FinancialBoost TargetHold ➝ Hold$13.00 ➝ $23.00
7/11/2024TD CowenBoost TargetBuy ➝ Buy$15.00 ➝ $25.00
7/11/2024Piper SandlerBoost TargetNeutral ➝ Neutral$16.00 ➝ $18.00
6/27/2024Jefferies Financial GroupBoost TargetHold ➝ Hold$14.00 ➝ $23.00
6/13/2024Bank of AmericaBoost TargetBuy ➝ Buy$22.00 ➝ $26.00
6/3/2024Bank of AmericaBoost TargetBuy ➝ Buy$17.25 ➝ $22.00
5/22/2024Canaccord Genuity GroupBoost TargetBuy ➝ Buy$20.00 ➝ $24.00
5/22/2024CitigroupDowngradeBuy ➝ Neutral$16.00 ➝ $20.00
5/7/2024Deutsche Bank AktiengesellschaftBoost TargetHold ➝ Hold$14.00 ➝ $16.00
5/7/2024Piper SandlerBoost TargetNeutral ➝ Neutral$11.00 ➝ $13.00
4/26/2024Seaport Res PtnReiterated RatingBuy
4/16/2024Jefferies Financial GroupReiterated RatingBuy ➝ Hold$17.00 ➝ $15.00
4/10/2024Canaccord Genuity GroupInitiated CoverageBuy$20.00
4/10/2024Canaccord Genuity GroupInitiated CoverageBuy$20.00
2/28/2024Imperial CapitalUpgradeIn-Line ➝ Outperform$16.00
2/27/2024CitigroupBoost TargetBuy ➝ Buy$12.00 ➝ $16.00
2/27/2024GuggenheimBoost TargetBuy ➝ Buy$15.00 ➝ $17.00
2/27/2024Piper SandlerBoost TargetNeutral ➝ Neutral$9.00 ➝ $11.00
2/27/2024Truist FinancialBoost TargetHold ➝ Hold$10.00 ➝ $13.00
2/26/2024Leerink PartnrsReiterated RatingMarket Perform
2/26/2024Leerink PartnersInitiated CoverageMarket Perform$10.00
1/5/2024Tigress FinancialBoost TargetBuy ➝ Buy$14.00 ➝ $15.00
12/7/2023Imperial CapitalInitiated CoverageInline$9.00
8/9/2023Truist FinancialLower TargetHold ➝ Hold$12.00 ➝ $10.00
8/8/2023Piper SandlerLower Target$11.00 ➝ $10.00
8/8/2023Credit Suisse GroupReiterated RatingOutperform ➝ Outperform$14.00
7/28/2023TD CowenInitiated CoverageOutperform$11.00
6/15/2023Tigress FinancialBoost Target$12.00 ➝ $14.00
5/30/2023Piper SandlerLower Target$12.00 ➝ $11.00
5/9/2023Bank of AmericaBoost Target$13.50 ➝ $15.00
5/9/2023Piper SandlerBoost Target$11.00 ➝ $12.00
4/27/2023GuggenheimBoost Target$15.00 ➝ $18.00
4/26/2023Piper SandlerBoost Target$10.00 ➝ $11.00
4/11/2023Robert W. BairdInitiated CoverageNeutral$10.00
3/1/2023Deutsche Bank AktiengesellschaftBoost Target$7.00 ➝ $9.00
3/1/2023Credit Suisse GroupBoost TargetOutperform$8.00 ➝ $14.00
2/28/2023GuggenheimReiterated RatingBuy$15.00
2/28/2023Truist FinancialBoost TargetHold$7.00 ➝ $12.00
2/28/2023Piper SandlerBoost TargetNeutral$7.00 ➝ $10.00
2/28/2023Bank of AmericaBoost TargetBuy$11.50 ➝ $13.50
2/28/2023CitigroupBoost TargetBuy$9.00 ➝ $14.00
2/9/2023Jefferies Financial GroupUpgradeHold ➝ Buy$7.00 ➝ $11.00
1/10/2023Tigress FinancialBoost Target$11.00 ➝ $12.00
1/3/2023Piper SandlerBoost Target$6.00 ➝ $7.00
11/15/2022CitigroupBoost Target$8.00 ➝ $9.00
11/8/2022Leerink PartnersUpgradeMarket Perform ➝ Outperform$5.00
11/8/2022Bank of AmericaUpgradeNeutral ➝ Buy$7.50 ➝ $8.50
10/17/2022Piper SandlerDowngradeOverweight ➝ Neutral$8.00 ➝ $6.00
9/7/2022Truist FinancialInitiated CoverageHold$7.00
8/15/2022GuggenheimBoost Target$12.00
8/10/2022Deutsche Bank AktiengesellschaftBoost Target$7.00 ➝ $8.00
8/10/2022Credit Suisse GroupBoost TargetOutperform$7.00 ➝ $8.00
8/9/2022Leerink PartnersBoost TargetUnderperform$4.00 ➝ $5.00
7/15/2022Leerink PartnersInitiated CoverageUnderperform$4.00
5/26/2022Piper SandlerLower TargetOverweight$8.00 ➝ $6.00
5/10/2022CitigroupLower Target$9.00 ➝ $6.00
4/13/2022GuggenheimInitiated CoverageBuy$10.00
3/10/2022Deutsche Bank AktiengesellschaftInitiated CoverageHold$7.00
2/23/2022Piper SandlerLower Target$12.00 ➝ $8.00
12/20/2021CitigroupLower TargetBuy$14.00 ➝ $9.00
12/1/2021Jefferies Financial GroupInitiated CoverageHold$7.00
11/11/2021Piper SandlerUpgradeNeutral ➝ Overweight$10.00 ➝ $12.00
7/6/2021Bank of AmericaInitiated CoverageNeutral$12.00
5/26/2021Credit Suisse GroupUpgradeNeutral ➝ Outperform
5/20/2021Credit Suisse GroupUpgradeNeutral ➝ Outperform$16.00
5/19/2021CitigroupBoost TargetBuy$16.00 ➝ $20.00
4/21/2021Truist FinancialInitiated CoverageHold
3/19/2021Piper SandlerLower TargetNeutral$20.00 ➝ $18.00
3/9/2021Credit Suisse GroupInitiated CoverageNeutral$16.00
3/2/2021CitigroupUpgradeNeutral ➝ Buy$23.00
2/17/2021CitigroupInitiated CoverageNeutral$23.00
2/12/2021Piper SandlerInitiated CoverageNeutral$20.00
2/8/2021Tigress FinancialInitiated CoverageBuy
(Data available from 11/21/2019 forward)

News Sentiment Rating

0.69 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 11 very positive mentions
  • 20 positive mentions
  • 3 negative mentions
  • 1 very negative mentions
Mentions as of
4/24/2024
  • 41 very positive mentions
  • 46 positive mentions
  • 7 negative mentions
  • 3 very negative mentions
Mentions as of
5/24/2024
  • 21 very positive mentions
  • 26 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
6/23/2024
  • 26 very positive mentions
  • 25 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
7/23/2024
  • 28 very positive mentions
  • 45 positive mentions
  • 10 negative mentions
  • 1 very negative mentions
Mentions as of
8/22/2024
  • 31 very positive mentions
  • 19 positive mentions
  • 11 negative mentions
  • 0 very negative mentions
Mentions as of
9/21/2024
  • 35 very positive mentions
  • 21 positive mentions
  • 8 negative mentions
  • 1 very negative mentions
Mentions as of
10/21/2024
  • 42 very positive mentions
  • 56 positive mentions
  • 6 negative mentions
  • 0 very negative mentions
Mentions as of
11/20/2024

Current Sentiment

  • 42 very positive mentions
  • 56 positive mentions
  • 6 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

Negative

Positive

Very Positive

Hims & Hers Health logo
Hims & Hers Health, Inc. operates a telehealth platform that connects consumers to licensed healthcare professionals in the United States, the United Kingdom, and internationally. The company offers a range of curated prescription and non-prescription health and wellness products and services available to purchase on its websites and mobile application directly by customers. It also provides prescription medication on a recurring basis and ongoing care from healthcare providers; and over-the-counter drug and device products, cosmetics, and supplement products primarily focusing on general wellness, sexual health and wellness, skincare, and hair care. In addition, the company's curated non-prescription products include melatonin and biotin in the wellness specialty category; moisturizers, creams, sunscreen, serum, face oil, and face wash in the skincare specialty; condoms, climax delay spray and wipes, vibrators, and lubricants in the sexual health and wellness specialty; and shampoos, conditioners, scalp scrubs, and topical treatments, such as minoxidil in the hair care specialty category. Further, it offers medical consultation and post-consultation support services, as well as health and wellness products through wholesale partners. Hims & Hers Health, Inc. is based in San Francisco, California.
Read More

Today's Range

Now: $21.80
Low: $21.44
High: $23.12

50 Day Range

MA: $20.21
Low: $15.82
High: $27.89

52 Week Range

Now: $21.80
Low: $7.51
High: $30.44

Volume

18,369,969 shs

Average Volume

9,423,281 shs

Market Capitalization

$4.76 billion

P/E Ratio

49.55

Dividend Yield

N/A

Beta

1.06

Frequently Asked Questions

What sell-side analysts currently cover shares of Hims & Hers Health?

The following Wall Street research analysts have issued stock ratings on Hims & Hers Health in the last year: Bank of America Co., Canaccord Genuity Group Inc., Citigroup Inc., Deutsche Bank Aktiengesellschaft, Guggenheim, Imperial Capital, Jefferies Financial Group Inc., Leerink Partners, Leerink Partnrs, Needham & Company LLC, Piper Sandler, Seaport Res Ptn, TD Cowen, TheStreet, Tigress Financial, and Truist Financial Co..
View the latest analyst ratings for HIMS.

What is the current price target for Hims & Hers Health?

0 Wall Street analysts have set twelve-month price targets for Hims & Hers Health in the last year. Their average twelve-month price target is $20.71, suggesting a possible downside of 4.4%. Canaccord Genuity Group Inc. has the highest price target set, predicting HIMS will reach $28.00 in the next twelve months. Leerink Partners has the lowest price target set, forecasting a price of $10.00 for Hims & Hers Health in the next year.
View the latest price targets for HIMS.

What is the current consensus analyst rating for Hims & Hers Health?

Hims & Hers Health currently has 1 sell rating, 8 hold ratings and 7 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Hold." A "hold" rating indicates that analysts believe investors should keep any existing positions they have in HIMS, but not buy more shares or sell existing shares.
View the latest ratings for HIMS.

What other companies compete with Hims & Hers Health?

Other companies that are similar to Hims & Hers Health include Fresenius Medical Care, Guardant Health, Option Care Health, Sotera Health and BrightSpring Health Services. Learn More about companies similar to Hims & Hers Health.

How do I contact Hims & Hers Health's investor relations team?

Hims & Hers Health's physical mailing address is 2269 CHESTNUT STREET SUITE 523, SAN FRANCISCO CA, 94123. The company's listed phone number is 415-851-0195 and its investor relations email address is [email protected]. The official website for Hims & Hers Health is www.forhims.com. Learn More about contacing Hims & Hers Health investor relations.